10-Q: Akari Therapeutics Reports First Quarter 2024 Results Amidst Strategic Shift

Akari Therapeutics reported a net loss of $5.6 million for the first quarter of 2024 and announced a strategic shift to focus on its PAS-nomacopan program and Peak Bio's ADC platform, suspending its HSCT-TMA program.

Summary

• Akari Therapeutics reported a net loss of $5.6 million for the first quarter of 2024, compared to a net income of $1.0 million in the same period last year.
• The company's operating expenses increased to $5.989 million, up from $4.594 million in the first quarter of 2023.
• Research and development expenses rose to $2.279 million, a 32% increase year-over-year, driven by increased clinical trial costs for the HSCT-TMA program and manufacturing expenses.
• General and administrative expenses also increased to $3.710 million, a 30% increase year-over-year, primarily due to higher legal and professional fees related to the proposed merger with Peak Bio.
• The company's cash balance stood at $1.310 million as of March 31, 2024, down from $3.845 million at the end of 2023.
• Akari has an accumulated deficit of $233.0 million as of March 31, 2024.
• The company has suspended its HSCT-TMA program to focus on its PAS-nomacopan program and Peak Bio's ADC platform.
• A reduction-in-force of approximately 67% of the workforce was implemented on May 1, 2024, with expected costs between $3.1 million and $3.2 million.
• The company entered into convertible promissory notes for $1.0 million on May 10, 2024, with existing investors and directors.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, a strategic shift involving the suspension of a key program, and a substantial reduction in workforce. While there are some positives, such as the focus on new programs and a small capital raise, the overall tone is negative due to the company's financial instability and operational restructuring.

Positives

• The company is strategically shifting its focus to its PAS-nomacopan program for Geographic Atrophy and Peak Bio's ADC platform, which may offer better long-term prospects.
• Akari is planning a pre-investigational new drug application meeting for PAS-nomacopan in the third quarter of 2024.
• The company has secured $1.0 million in convertible promissory notes to provide operating cash.

Negatives

• The company reported a net loss of $5.6 million for the first quarter of 2024, a significant decrease from the net income of $1.0 million in the same period last year.
• The company's cash balance has decreased to $1.310 million, raising concerns about its ability to fund operations.
• The company has suspended its HSCT-TMA program, which was a key focus area.
• A significant reduction-in-force of 67% of the workforce was implemented, which may impact operations and morale.
• The company has a substantial accumulated deficit of $233.0 million.

Risks

• The company's cash balance of $1.3 million is not sufficient to fund operations for the next year, raising substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations and may not be able to do so on acceptable terms.
• The company's shares may be delisted from Nasdaq if it fails to regain compliance with the minimum shareholders' equity requirement.
• The company's strategic shift and reduction-in-force may not achieve the intended outcomes and could negatively impact operations.
• The merger with Peak Bio is subject to various conditions and may not be completed.
• The company is subject to risks associated with clinical trials, regulatory approvals, and competition.

Future Outlook

The company will focus on its PAS-nomacopan program for Geographic Atrophy and Peak Bio's ADC platform. They expect to hold a pre-investigational new drug application meeting in the third quarter of 2024. The company is also seeking additional funding through financings of equity and/or debt securities and may engage in strategic research and development collaborations.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding for future operations.
• Management has concluded that there is substantial doubt regarding the company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

Industry Context

The biotechnology industry is characterized by high risk and high reward, with companies often facing significant challenges in funding and clinical development. Akari's strategic shift and restructuring are indicative of the need for companies to adapt to changing market conditions and prioritize their pipelines. The merger with Peak Bio is a strategic move to diversify the company's technology and pipeline.

Comparison to Industry Standards

• Akari's cash burn rate and accumulated deficit are not uncommon for clinical-stage biotech companies, but the company's current cash position is significantly below the industry average for companies at a similar stage of development.
• The decision to suspend the HSCT-TMA program and focus on other assets is a common strategy for companies facing financial constraints, similar to decisions made by companies such as Athersys and Cellectar Biosciences.
• The merger with Peak Bio is a strategic move to diversify the company's technology and pipeline, similar to mergers seen in the industry such as the merger between Immunomedics and Gilead.
• The reduction-in-force is a common cost-cutting measure in the biotech industry, similar to actions taken by companies such as Biogen and Novartis.

Management Changes

Related Party Transactions

• The company leases office space from The Doctors Laboratory (TDL), where David Byrne, a former director, is the CEO and Dr. Prudo is the non-Executive Chairman.
• The company received laboratory testing services from TDL.
• The company entered into convertible promissory notes with directors Dr. Prudo and Dr. Patel.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting.
• Employees have been impacted by the reduction-in-force, with approximately 67% of the workforce being laid off.
• Customers and suppliers may be affected by the company's strategic shift and restructuring.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will focus on its PAS-nomacopan program for Geographic Atrophy and Peak Bio's ADC platform.
• The company expects to hold a pre-investigational new drug application meeting in the third quarter of 2024.
• The company will seek additional funding through financings of equity and/or debt securities.
• The company will work to complete the merger with Peak Bio.
• The company will work with the FDA to define the best path for the HSCT-TMA technology.

Key Dates

Keywords

Akari Therapeutics, Nomacopan, PAS-nomacopan, HSCT-TMA, Geographic Atrophy, ADC platform, Merger, Clinical Trials, Biotechnology, Financial Results, Restructuring, Capital Raise